摘要
目的分析联合S100A12和降钙素原(PCT)检测在急性呼吸窘迫综合征(ARDS)患者预后中的参考价值。方法选取2017年4月-2019年4月本院收治的82例ARDS患者为研究对象。根据患者的ARDS病情严重程度将其分为轻度组、中度组和重度组,检测患者入院时的S100A12、PCT水平,使用受试者工作特征曲线分析S100A12、PCT以及联合检测在ARDS患者预后中的参考价值。结果随着病情的加重,S100A12和PCT水平均随之显著增加(P <0.05);死亡组的血清S100A12和PCT水平均显著高于生存组;S100A12的曲线下面积(AUC)为0.753 (95%CI:0.704~0.852),灵敏度及特异度分别为0.745、0.753;PCT的AUC为0.794(95%CI:0.725~0.882),灵敏度及特异度分别为0.750、0.803;联合检测的AUC为0.898(95%CI:0.790~0.974),灵敏度及特异度分别为0.853、0.907。结论联合S100A12和PCT检测在ARDS患者预后中的参考价值较好,值得进一步验证使用。
Objective To analyze the reference value of combined detection of S100 A12 and procalcitonin( PCT) in the prognosis of patients with acute respiratory distress syndrome( ARDS). Methods Eighty two ARDS patients admitted to our hospital from April 2017 to April 2019 were selected as subjects. According to the severity of ARDS,the patients were divided into mild,moderate and severe groups. The S100 A12 and PCT levels were measured at admission. The receiver operating characteristic curve was used to analyze the reference value of S100 A12,PCT and the reference value of combined detection in ARDS patients. Results As the condition worsened,S100 A12 and PCT levels increased significantly( P < 0. 05). Serum S100 A12 and PCT levels in the death group were significantly higher than the survival group;the area under the curve( AUC) of S100 A12 was 0. 753( 95% CI: 0. 704-0. 852),the sensitivity and specificity were 0. 745,0. 753;the AUC of PCT was 0. 794( 95% CI: 0. 725-0. 882),sensitivity and specificity were 0. 750,0. 803;AUC of combined detection was 0. 898( 95% CI:0. 790-0. 974),sensitivity and specificity were respectively 0. 853,0. 907. Conclusion The combined value of S100 A12 and PCT in the prognosis of patients with ARDS is good and worthy of further verification.
作者
方莉
徐秀萍
FANG Li;XU Xiu-ping(Department of Geriatric Medicine,the Third Hospital of Quzhou,Quzhou,Zhejiang 324000,China)
出处
《中国卫生检验杂志》
CAS
2021年第1期73-75,78,共4页
Chinese Journal of Health Laboratory Technology